Acute Diarrhea
Conditions
Keywords
Children, Diarrhea, Human milk oligosaccharides
Brief summary
Assessment of the impact of oral Human Milk Oligosaccharides (HMO) application on acute diarrhoea and the development of prolonged and persistent diarrhoea in paediatric patients hospitalized with acute diarrhoea.
Detailed description
The trial is single site, double blind, randomized of HMO addition (1.5 g /day) to standard of care in paediatric diarrhoea patients. HMO application and follow-up of the children at home will be done for 2 weeks. Control patients receive only the standard of care (ORS plus zinc). A breastfed group of diarrhoea patients will serve as reference group. The total sample size is 495 patients. Patients will be females and males aged 6 months to 2 years old with acute diarrhoea.
Interventions
Sponsors
Société des Produits Nestlé (SPN)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Months to 2 Years
Healthy volunteers
No
Inclusion criteria
Non breast-fed children (group I and group II): 1. Both male and female children between the ages of 6 months to 2 years. 2. Acute diarrhoea (\<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc. 3. Guardian is willing to have the child admitted to the hospital as an inpatient until resolution of diarrhea and to return to the clinic with the child on Day 14 after admission for a final evaluation. 4. Written informed consent must be obtained prior to admission to this study. 5. The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.
Exclusion criteria
Non breast-fed children (group I and group II): 1. Children of either sex who are fully or partially breast-fed until one week before enrolment (since breastfed children receive naturally HMO, their inclusion into the ORS/zinc or HMO/ORS/zinc arms would critically interfere with the study question; depending on children's age 30 to 50 % of mothers would do so at icddr,b). However, an unblinded reference group will be constituted by age-matched children who are breastfed at the moment of hospitalization for acute diarrhea and where the mothers want to continue breastfeeding on the study ward (so breastfeeding is only an exclusion for the randomized groups). 2. Suspected or confirmed cholera as detected by a positive DF examination in stool collected on admission. (The large volume and quick evacuation of stool could interfere with product presence in the gut) 3. Symptom duration \> 48 hours at screening. 4. Vomiting severity that is likely to make administration and retention of test product impossible. 5. Severe malnutrition defined (using z-scores) as: severe stunting (SS; height-for-age z-score \< -3.00); severe underweight (SU; weight-for-age z-score \< -3.00), and severe wasting (SW; weight-for-height z-score \< -3.00), using the World Health Organization reference value. Moderate malnutrition was defined as follows: moderate stunting (height-for-age z-score -3.00 to \< -2.00); moderate underweight (weight-for-age z-score -3.00 to \< -2.00); and moderate wasting (weight-for-height z-score -3.00 to \< -2.00). We considered children as well-nourished if their z-scores for weight-for-age, height-for-age and weight-for-height z-score were form -2.00 to +1.00. Children with moderate malnutrition will be enrolled since they develop with higher frequency PD). 6. Child already receiving antibiotics or anti-motility drugs for this diarrhea episode prior to screening. 7. Children with any food allergy. Breast-fed children, (Group III - Reference group) 1. Exclusive Breastfed children Either sex: Male and female 2. Age 6-12 month 3. Acute diarrhoea (\<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc. 4. Written informed consent must be obtained prior to admission to this study. 5. The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement (change) of clinical symptoms of diarrhea | Day1, Day2, Day3, Day4, Day5, Day6, Day7 | Passage of the last abnormal stool prior to formed/ soft stools during two consecutive 8-hour periods. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Weight gain | Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14 | — |
| Adverse events | Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14 | — |
| Daily stool frequency | Day1, Day2, Day3, Day4, Day5, Day6, Day7 | — |
| Stools output | Day1, Day2, Day3, Day4, Day5, Day6, Day7 | Stools output, expressed as g/kg of body weight (cumulative output) |
| The duration of vomiting | Day1, Day2, Day3, Day4, Day5, Day6, Day7 | — |
| Change in Z-score | Day1, Day14 | — |
| The amount of ORS to correct dehydration expressed as ml ORS /kg body weight, daily and cumulative input | Day1, Day2, Day3, Day4, Day5, Day6, Day7 | — |
| The number of vomiting | Day1, Day2, Day3, Day4, Day5, Day6, Day7 | — |
Countries
Bangladesh
Outcome results
None listed